All News

Hannah Weber joins HOPO Therapeutics as VP, Strategy & Business Development

New strategic direction for the company announced

Co-founder and CEO Julian Rees, Ph.D. discusses a shift in HOPO’s focus area in last week’s newsletter READ

HOPO Therapeutics joins Pad-13 program at Berkeley SkyDeck

The UC Berkeley-based startup incubator / accelerator provides a vast network of resources, contacts, and guidance to help us achieve our mission

HOPO Therapeutics team awarded 2021 Bakar Fellowship from UC Berkeley

Rebecca Abergel, Ph.D. and Julian Rees, Ph.D. have received a Bakar Fellowship from UC Berkeley to advance the commercial development of our heavy metal chelator 3,4,3,-LI(1,2-HOPO)

Rebecca Abergel granted tenure

Huge congratulations to co-founder Rebecca Abergel, Ph.D. on her promotion to Associate Professor with tenure!

Letter to stakeholders from CEO Julian Rees

Co-founder and CEO Julian Rees, Ph.D. sent a letter yesterday with important company news and updates - you can read it here. Join our mailing list to stay on top of more news!